NewAmsterdam Pharma Company N.V. (NAMS) Free cash flow 2021–2025
NewAmsterdam Pharma Company N.V. (NAMS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$148.0MFY2025 · since FY2021: -$29.5M → -$148.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$148.0M | +7.0% |
| FY2024 | -$159.2M | -12.7% |
| FY2023 | -$141.2M | -1452.4% |
| FY2022 | $10.4M | +135.4% |
| FY2021 | -$29.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice